Shattuck Labs, Inc. (STTK)
| Market Cap | 351.20M +611.8% |
| Revenue (ttm) | 1,000,000 -78.3% |
| Net Income | -49.87M |
| EPS | -0.59 |
| Shares Out | 76.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,134,079 |
| Open | 4.952 |
| Previous Close | 4.800 |
| Day's Range | 4.370 - 5.170 |
| 52-Week Range | 0.712 - 8.330 |
| Beta | 1.09 |
| Analysts | Strong Buy |
| Price Target | 12.50 (+172.93%) |
| Earnings Date | May 7, 2026 |
About STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical... [Read more]
Financial Performance
In 2025, Shattuck Labs's revenue was $1.00 million, a decrease of -82.52% compared to the previous year's $5.72 million. Losses were -$48.81 million, -35.28% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for STTK stock is "Strong Buy." The 12-month stock price target is $12.5, which is an increase of 172.93% from the latest price.
News
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
AUSTIN, Texas and DURHAM, N.C., June 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-...
Citi opens ‘upside 30-day catalyst watch’ on Shattuck into data
Citi added an “upside 30-day catalyst watch” on Shattuck Labs (STTK) after upgrading the shares to Buy with a $7 price target into the Q2 Phase 1 data for SL-325…
Shattuck Labs upgraded to Buy from Neutral at Citi
Citi upgraded Shattuck Labs (STTK) to Buy from Neutral with a $7 price target The stock has sold doff roughly 30% heading into initial Phase 1 data for SL-325 in…
Shattuck Labs price target raised to $11 from $8 at Wedbush
Wedbush raised the firm’s price target on Shattuck Labs (STTK) to $11 from $8 and keeps an Outperform rating on the shares. The firm notes the company reiterated guidance for…
Shattuck Labs reports Q1 EPS (13c), consensus (13c)
As of March 31, 2026, cash and cash equivalents and short-term investments were $90.4M, vs. $60.9M as of March 31, 2025. “We are pleased to have completed enrollment in our…
Shattuck Labs sees cash and cash equivalents sufficient into 2029
06:56 EDT Shattuck Labs (STTK) sees cash and cash equivalents sufficient into 2029
Shattuck Labs Quarterly report: Q1 2026
Shattuck Labs has published its Q1 2026 quarterly earnings report on May 7, 2026.
Shattuck Labs Earnings release: Q1 2026
Shattuck Labs released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Shattuck Labs Slides: Corporate presentation
Shattuck Labs has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
AUSTIN, Texas and DURHAM, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of pote...
Shattuck Labs initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Shattuck Labs (STTK) with an Overweight rating. The stock’s more than 800% rise over the last 12 months reflects enthusiasm for its DR3 and TL1A…
Shattuck Labs price target raised to $18 from $6 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Shattuck Labs (STTK) to $18 from $6 and keeps a Buy rating on the shares. The firm increased its projected SL-325 probability…
Shattuck Labs Proxy statement: Proxy filing
Shattuck Labs filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Shattuck Labs Proxy statement: Proxy filing
Shattuck Labs filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Shattuck Labs management to meet with Piper Sandler
Meetings to be held in Boston on April 7, in Greenwich, CT on April 8 and in New York on April 9 hosted by Piper Sandler.
Citi ups Shattuck Labs target, opens ‘upside 90-day catalyst watch’
Citi raised the firm’s price target on Shattuck Labs (STTK) to $7 from $4 and keeps a Neutral rating on the shares. Citi also added an “upside 90-day catalyst watch”…
Shattuck Labs price target raised to $8 from $4 at Wedbush
Wedbush raised the firm’s price target on Shattuck Labs (STTK) to $8 from $4 and keeps an Outperform rating on the shares. The firm notes the company reported earnings, confirmed…
Shattuck Labs transferred with Buy rating at Needham
Needham analyst Joseph Stringer put a Buy rating and $14 price target on Shattuck Labs (STTK) following a transfer of coverage. The firm previously had a Hold rating on the…
Shattuck Labs Slides: Corporate presentation
Shattuck Labs has posted slides in relation to its latest quarterly earnings report, which was published on March 5, 2026.
Shattuck Labs Annual report: Q4 2025
Shattuck Labs has published its Q4 2025 annual report on March 5, 2026.
Shattuck Labs Earnings release: Q4 2025
Shattuck Labs released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
Shattuck Labs reports Q4 EPS (12c), consensus (13c)
Reports Q4 revenue $0, consensus $166,670. As of December 31, 2025, cash and cash equivalents and short-term investments were approximately $78.1M, as compared to $73.0M as of December 31, 2024.
Shattuck Labs expects available cash to fund operations into 2029
The company said, “As of December 31, 2025, cash and cash equivalents and short-term investments were approximately $78.1M. Shattuck’s current cash and cash equivalents and short-term investments, inc...
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
AUSTIN, Texas and DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of po...
Shattuck Labs Transcript: TD Cowen 46th Annual Health Care Conference
A novel DR3 blocking antibody program aims to overcome immunogenicity and efficacy limitations of TL1A blockers in IBD. Phase I data for SL-325 will be released in Q2, with a phase IIb Crohn's trial starting in Q3. Bispecifics and lifecycle management strategies are also advancing.